Healthcare Industry News: Stereotactic
News Release - September 7, 2007
Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007BARCELONA, Spain, Sept. 7 (HSMN NewsFeed) -- Varian Medical Systems (NYSE: VAR ), world leader in advanced radiotherapy solutions for treating cancer, is demonstrating its full range of technologies and products aimed at improving the speed and precision of radiotherapy at the 2007 European Society for Therapeutic Radiology and Oncology (ESTRO) meeting in Barcelona, Spain from September 8th-13th.
Among the new product introductions on show will be the Smart Segmentation(TM) feature for Varian's Eclipse(TM) treatment planning system. Smart Segmentation is the world's first fully automatic software tool that identifies and outlines organs and other structures of interest within diagnostic images of the thorax and male pelvis. Up to now, identifying structures to be irradiated or protected during radiotherapy treatments had to be done by hand. Eclipse will also display another intelligent planning tool that automatically selects the optimal treatment beam angle for each patient. Additionally, Varian will demonstrate 4D planning software to account for organ motion during precision radiotherapy treatments.
Varian will also be discussing the new high-definition multi-leaf collimator (HD120 MLC). This high-definition collimator, with increased resolution utilizing smaller leaves, will be available with the company's Trilogy® Tx medical linear accelerator and addresses the unique needs of Stereotactic radiosurgery (SRS) and Stereotactic body radiotherapy (SBRT).
Along with the market-leading On Board Imager® device for clinically-practical image guided radiotherapy (IGRT), Varian will also be demonstrating its Trilogy and Clinac® linear accelerators, its Acuity imaging device for planning and simulating treatments and its full range of planning and delivery tools for brachytherapy.
For the first time, Varian will be exhibiting its spot-scanning proton therapy solutions. Varian acquired Accel in January this year and visitors to ESTRO will be able to see how the Germany-based technology leader in particle therapy is being integrated into Varian Medical Systems. Varian can be found at Booths 8, 9 and 52.
Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068, firstname.lastname@example.org
About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 4,400 people who are located at manufacturing sites in North America and Europe and in its 60 sales and support offices around the world. For more information, visit http://www.varian.com/.
Forward Looking Statements
Statements in this press release regarding future business, events, plans, objectives, expectations, estimates, and other similar matters, including, but not limited to, statements using the terms "can" and "expect," constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including, but not limited to, the risks described in the company's Annual Report on Form 10-K and other reports filed from time to time by the Company with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this press release. The Company assumes no obligation to update or revise these forward-looking statements because of new information, future events, or otherwise.
Source: Varian Medical Systems
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsLong-Term Results from SABR-COMET Further Demonstrate Effectiveness of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Metastatic Cancers
RaySearch Enters Into Interoperability Agreement With Varian
Varian Launches New Noona(R) Capabilities to Meet Growing Demand for Remote Cancer Patient Monitoring in Response to COVID-19's Impact on Healthcare